New Product Launches Ensured Growth For Stada CHC In 2024

 
• By David Ridley

Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.

STADA
Stada's Consumer Healthcare business grows 3% in 2024 • Source: Shutterstock: 360b

More from Europe

More from Strategy